ClinicalTrials.gg
RecruitingNCT04975178MTBVACN3Updated Feb 10, 2025

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

A Phase 3 interventional study of MTBVAC and BCG in Tuberculosis, sponsored by Biofabri, S.L. Recruiting at 1 site in South Africa. Open to participants aged 5 Minutes to 7 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Biofabri, S.L · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,120
Allocation
Randomized
Ages
5 Minutes to 7 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Tuberculosis with a site in South Africa — 21 open to participants now, 35 under way, 8 of them phase 3. Tuberculosis · South Africa.

Planned enrollment
12th of 176
7,120 · median 214
Started
2022
with 12 others
Phase 3
23 of 210
3 open now
Primary completion
2029-02
later than 32 of 34 live
Registered
164th of 210
by date

Among the 210 studies in Tuberculosis with a site in South Africa, this one is the 12th largest by planned enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2022, is one of 23 in phase 3, reaches primary completion later than 32 of the 34 other live ones, and was the 164th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

21 of the 210 studies in Tuberculosis with a site in South Africa are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 5 Minutes to 7 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Tuberculosis with a site in South Africa, or all of them as a file.
02

Study summary

The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to HIV-infected and HIV-uninfected mothers as compared to standard of care BCG vaccination. The proposal builds upon a group of TB vaccine development partners in Europe and sub-Saharan Africa established in a previous EDCTP-supported project. It creates an expanded consortium of clinical trial partners for the optimal implementation of a large infant efficacy trial of MTBVAC in high TB incidence settings. New capacity for efficacy trials in infants will be a valuable resource for the TB vaccine development community. The proposal will create a network of institutions in three TB endemic African countries with enhanced laboratory capacity to conduct TB vaccine immunology studies and to bio-bank samples to discover immune correlates of vaccine-mediated protection.

Read the detailed description

A new effective tuberculosis (TB) vaccine is essential to achieve World Health Organization End TB goals and eliminate TB by 2050. The optimal long-term strategy would be a combination of serial mass campaigns in adults, coupled with universal newborn vaccination. Newborns are the only human population without prior mycobacterial exposure in TB endemic countries and we hypothesize that live attenuated mycobacterial vaccines will offer better protection to this naïve population compared to adults.

The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to HIV-infected and HIV-uninfected mothers as compared to standard of care BCG vaccination. The proposal builds upon a group of TB vaccine development partners in Europe and sub-Saharan Africa established in a previous EDCTP-supported project. It creates an expanded consortium of clinical trial partners for the optimal implementation of a large infant efficacy trial of MTBVAC in high TB incidence settings. New capacity for efficacy trials in infants will be a valuable resource for the TB vaccine development community. The proposal will create a network of institutions in three TB endemic African countries with enhanced laboratory capacity to conduct TB vaccine immunology studies and to bio-bank samples to discover immune correlates of vaccine-mediated protection.

MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. The hypothesis is that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.

Phase 1 studies showed that MTBVAC was safe and immunogenic in naïve adults and newborns, and evoked an immune response that exceeded the magnitude of BCG-induced immune responses. Larger dose-defining Phase 2a studies in newborns and in adults at extended dose-ranges to confirm these findings will be finalised in early 2021, and allow selection of a vaccine dose to progress into the proposed multi-centre efficacy trial in infants.

03

Conditions studied

  • Tuberculosis

Browse trials for

04

Who can participate

Ages eligible
5 Minutes to 7 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female newborns within seven days of birth.
  • Written informed maternal consent, including permission to access maternal antenatal, postnatal, and infant medical records.
  • Infant participants and their caregivers available for trial follow-up and display the willingness and capacity to comply with trial procedures.
  • Newborns must be in good general health during pregnancy and delivery, as assessed by medical history and targeted physical examination.
  • Birth weight ≥ 2450 grams.
  • Apgar score at 5 minutes ≥ 7.
  • A maternal test result (rapid test, enzyme-linked immunosorbent assay (ELISA), or Polymerase chain reaction (PCR)) taken within 30 days of delivery, or within seven days post-partum must be available and documented if HIV uninfected. If the mother is HIV infected, then she must be on antiretroviral (ARV) therapy as per in-country guidelines with a viral load of \<50 copies/mL (within six months of labour).
  • Estimated gestational age ≥ 37 weeks.
  • Mother has not participated in a clinical trial within three months prior to the infant's birth.
  • Mother has never participated in a TB vaccine trial before.
  • Infant may not participate in any other clinical trials.

Exclusion criteria

Exclusion Criteria:

Receipt of BCG vaccination prior to enrolment.

  • Significant antenatal, intrapartum, or postpartum complications that may affect the health of the newborn.
  • Skin condition, bruising or birth mark at the intended injection site.
  • Maternal test (rapid test, ELISA, or PCR) result not available.
  • HIV exposed Newborn's HIV PCR result positive or not available.
  • Maternal history of TB during pregnancy.
  • History of close/household contact with a TB patient, antenatal or postnatal, whether maternal, other family member or another household member who has not yet completed TB treatment.
  • Clinically suspected neonatal sepsis.
  • Any severe congenital malformation.
  • History or evidence of any systemic disease on examination, or any illness that in the opinion of the Investigator may interfere with the evaluation of the safety and immunogenicity of the vaccine. Neonatal jaundice not considered is not an exclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,120 participants (estimated)

Study arms

  • Experimental
    MTBVAC

    Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results. MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vaccine must be stored at +2°C to +8°C. Reconstituted MTBVAC vaccine must be stored at +2ºC to +8ºC and administered as soon as possible, within 4 hours of reconstitution. A single vaccine vial will be used for each participant.

    Biological: MTBVAC

  • Active comparator
    BCG

    BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth. One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial. BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC.

    Biological: BCG

Interventions

  • BiologicalMTBVAC

    MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.

  • BiologicalBCG

    BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.

06

What researchers measure

Primary outcomes

  1. To demonstrate efficacy in terms of incidence of MTBVAC against TB disease in healthy HU and HEU newborns compared to BCG

    Primary: Time from vaccination to diagnosis of first confirmed or unconfirmed TB disease, which might be right-censored due to loss to follow-up, death, or successful completion of the study without acquiring TB disease from day of vaccination. Secondary: Confirmed TB disease, which might be right-censored due to loss to follow-up, death, or successful completion of the study without acquiring TB from day of vaccination. Exploratory: i) Time from vaccination to diagnosis of first unconfirmed or unlikely TB disease, which might be right-censored due to loss to follow-up, death, or successful completion of the study without acquiring TB disease from day of vaccination. ii) Confirmed or unconfirmed TB, which might be right-censored due to loss to follow-up, death, or successful completion of the study without acquiring TB carried out with a washout period of 90 days after vaccination. iii) Confirmed TB disease; iv) Unconfirmed or unlikely TB disease (ver ii for iii and iv).

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

Secondary outcomes

  1. To assess the safety and reactogenicity of MTBVAC in healthy HU and HEU newborns compared to BCG.

    Incidence and severity of: Solicited AEs; Local solicited AEs (injection-site reactions): pain, erythema (redness), swelling, and induration (collected up to Day 10), and ulceration, drainage/discharge, and scarring (collected up to Day 56); Systemic solicited AEs: fever, irritability, vomiting, diarrhea, and skin rash (collected up to Day 10). Unsolicited AEs: MAAEs; Medically un-attended AEs. Solicited AEs with onset after Day 10: Local solicited AEs (injection-site reactions): pain, erythema (redness), swelling, and induration. Systemic solicited AEs: fever, irritability, vomiting, diarrhea, and skin rash. Solicited AEs with onset after Day 56: ulceration, drainage/discharge, and scarring; AESIs, SAEs

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

Other outcomes

  1. Tertiary objective: To assess immunogenicity of MTBVAC in healthy HU and HEU newborns.

    • Frequencies and co-expression patterns of CD4 and CD8 T cells expressing IFNγ, TNF, IL-2, IL-17, and/or IL-22 induced by MTBVAC or BCG vaccination detected by WB-ICS after in vitro stimulation with MTBVAC, BCG, or a megapool of mycobacterial peptides.

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

  2. Exploratory objective: To assess immunogenicity of MTBVAC in healthy HU and HEU newborns.

    Qualitative (positive or negative) and quantitative (TB Ag-Nil IFNγ concentration) QFT-Gold Plus assay results (QFT conversion will be defined as a positive test without a prior positive test; QFT reversion will be defined as a negative test following a positive test).

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

  3. Exploratory objective: To biobank samples for (future) biomarker studies to identify immunological correlates of vaccine-induced protection and biomarkers of risk for TB disease

    • The following samples will be collected and biobanked for future studies to investigate the immune correlates of TB infection: * PBMC * Plasma * Paxgene The analyses will be described in a separate document.

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

  4. Exploratory objective: To assess the non-specific effects of MTBVAC in healthy HU and HEU newborns compared to BCG.

    Primary • SAEs (hospitalization, death) due to non-TB infectious diseases classified as MedDRA SOC Infections and infestations occurring from Days 0 to 42. Secondary * MAAEs due to non-TB infectious diseases classified as MedDRA SOC Infections and infestations occurring from Days 0 to 42. * SAEs (hospitalization, death) due to non-TB infectious diseases classified as MedDRA SOC Infections and infestations occurring from Day 42 to EoSe. * MAAEs due to non-TB infectious diseases classified as MedDRA SOC Infections and infestations occurring from Day 42 to EoSe. * SAEs (hospitalization, death) occurring from Days 0 to 42 (or receipt of another vaccine type). * MAAEs occurring from Days 0 to 42 (or receipt of another vaccine type). * SAEs (hospitalization, death) from Day 42 to EoSe. * MAAEs from Day 42 to EoSe.

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

  5. Exploratory objective: To assess TB case definitions determined by study-specific TB investigations compared to non-study solicited TB investigations in South Africa

    * Time from vaccination to diagnosis of first confirmed or unconfirmed TB disease, which might be right-censored due to loss to follow-up, death, or successful completion of the study without acquiring TB disease from the day of the vaccination. * Time from vaccination to diagnosis of first confirmed TB disease, which might be right-censored due to loss to follow-up, death, or successful completion of the study without acquiring TB disease from the day of the vaccination.

    Time frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.

07

Study locations

1 of 1 sites recruiting
  • South African Tuberculosis Initiative, Brewelskloof Hospital
    Worcester, Western Cape 6850, South Africa
    Recruiting
08

References and documents

Publications

  • Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, Geldenhuys H, Shenje J, Luabeya AKK, Murillo I, Doce J, Aguilo N, Marinova D, Puentes E, Rodriguez E, Gonzalo-Asensio J, Fritzell B, Thole J, Martin C, Scriba TJ, Hatherill M; MTBVAC Clinical Trial Team. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019 Sep;7(9):757-770. doi: 10.1016/S2213-2600(19)30251-6. Epub 2019 Aug 12. PubMed 31416768 ↗
  • Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, Mayor CE, Rettby N, Jaton K, Vallotton L, Lazor-Blanchet C, Doce J, Puentes E, Marinova D, Aguilo N, Martin C. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015 Dec;3(12):953-62. doi: 10.1016/S2213-2600(15)00435-X. Epub 2015 Nov 17. PubMed 26598141 ↗
  • Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013 Oct 1;31(42):4867-73. doi: 10.1016/j.vaccine.2013.07.051. Epub 2013 Aug 17. PubMed 23965219 ↗
  • Aguilo N, Gonzalo-Asensio J, Alvarez-Arguedas S, Marinova D, Gomez AB, Uranga S, Spallek R, Singh M, Audran R, Spertini F, Martin C. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat Commun. 2017 Jul 14;8:16085. doi: 10.1038/ncomms16085. PubMed 28706226 ↗
  • Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012 Mar;54(6):784-91. doi: 10.1093/cid/cir951. Epub 2012 Jan 19. PubMed 22267721 ↗
  • Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol. 1999 Oct;34(2):257-67. doi: 10.1046/j.1365-2958.1999.01593.x. PubMed 10564470 ↗
  • Copin R, Coscolla M, Efstathiadis E, Gagneux S, Ernst JD. Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine. 2014 Oct 14;32(45):5998-6004. doi: 10.1016/j.vaccine.2014.07.113. Epub 2014 Sep 6. PubMed 25211768 ↗
  • Gonzalo-Asensio J, Marinova D, Martin C, Aguilo N. MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. Front Immunol. 2017 Dec 15;8:1803. doi: 10.3389/fimmu.2017.01803. eCollection 2017. PubMed 29326700 ↗
  • Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, Huygen K, Hernandez-Pando R, Thole J, Behr M, Gicquel B, Martin C. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS One. 2008;3(10):e3496. doi: 10.1371/journal.pone.0003496. Epub 2008 Oct 23. PubMed 18946503 ↗
  • Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Hatherill M, Hesseling AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, Madhi S, Makhene M, Marais BJ, McNeeley DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis. 2012 May 15;205 Suppl 2(Suppl 2):S199-208. doi: 10.1093/infdis/jis008. Epub 2012 Mar 22. PubMed 22448023 ↗
  • Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, Mayner RE, Thole J, Walker KB, Liu M, Lambert PH; AERAS Global TB Vaccine Foundation; World Health Organization. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine. 2005 May 31;23(29):3753-61. doi: 10.1016/j.vaccine.2005.03.001. Epub 2005 Mar 24. PubMed 15893612 ↗
  • Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15520-5. doi: 10.1073/pnas.1404386111. Epub 2014 Oct 6. PubMed 25288770 ↗
  • Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, Donald PR, Wilkinson RJ, Marais BJ. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010 Nov;10(11):803-12. doi: 10.1016/S1473-3099(10)70138-9. Epub 2010 Sep 6. PubMed 20822958 ↗
  • Scriba TJ, Kaufmann SH, Henri Lambert P, Sanicas M, Martin C, Neyrolles O. Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. J Infect Dis. 2016 Sep 1;214(5):659-64. doi: 10.1093/infdis/jiw228. Epub 2016 May 30. PubMed 27247343 ↗
  • Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, Gao Q, Kato-Maeda M, Ballif M, Egger M, Macedo R, Mardassi H, Moreno M, Tudo Vilanova G, Fyfe J, Globan M, Thomas J, Jamieson F, Guthrie JL, Asante-Poku A, Yeboah-Manu D, Wampande E, Ssengooba W, Joloba M, Henry Boom W, Basu I, Bower J, Saraiva M, Vaconcellos SEG, Suffys P, Koch A, Wilkinson R, Gail-Bekker L, Malla B, Ley SD, Beck HP, de Jong BC, Toit K, Sanchez-Padilla E, Bonnet M, Gil-Brusola A, Frank M, Penlap Beng VN, Eisenach K, Alani I, Wangui Ndung'u P, Revathi G, Gehre F, Akter S, Ntoumi F, Stewart-Isherwood L, Ntinginya NE, Rachow A, Hoelscher M, Cirillo DM, Skenders G, Hoffner S, Bakonyte D, Stakenas P, Diel R, Crudu V, Moldovan O, Al-Hajoj S, Otero L, Barletta F, Jane Carter E, Diero L, Supply P, Comas I, Niemann S, Gagneux S. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet. 2016 Dec;48(12):1535-1543. doi: 10.1038/ng.3704. Epub 2016 Oct 31. PubMed 27798628 ↗
  • Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitie MA, Diacon A, Evans TG, Gillard P, Hellstrom E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 2019 Dec 19;381(25):2429-2439. doi: 10.1056/NEJMoa1909953. Epub 2019 Oct 29. PubMed 31661198 ↗
  • Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021-8. doi: 10.1016/S0140-6736(13)60177-4. PubMed 23391465 ↗
  • Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, Dobbelaer R, Grode L, Liu MA, Fruth U, Lambert PH. The second Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine. 2010 Mar 8;28(11):2259-70. doi: 10.1016/j.vaccine.2009.12.083. Epub 2010 Jan 20. PubMed 20074686 ↗
  • White AD, Sibley L, Sarfas C, Morrison A, Gullick J, Clark S, Gleeson F, McIntyre A, Arlehamn CL, Sette A, Salguero FJ, Rayner E, Rodriguez E, Puentes E, Laddy D, Williams A, Dennis M, Martin C, Sharpe S. MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. NPJ Vaccines. 2021 Jan 4;6(1):4. doi: 10.1038/s41541-020-00262-8. PubMed 33397991 ↗
  • Whitehead J. Overrunning and underrunning in sequential clinical trials. Control Clin Trials. 1992 Apr;13(2):106-21. doi: 10.1016/0197-2456(92)90017-t. PubMed 1316826 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Feb 2029, 76 months after the start.

Of 40 phase 3 interventional studies under Tuberculosis, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 76. This study's planned 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jul 23, 2021
StartActual
Oct 17, 2022
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04975178
Lead sponsor
Biofabri, S.L
Collaborators
TuBerculosis Vaccine Initiative, University of Cape Town, Institut Pasteur de Madagascar, Biomedical Research Center EPLS, Universidad de Zaragoza, University of Stellenbosch, University of KwaZulu, Wits Health Consortium (Pty) Ltd
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Oct 17, 2022
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Feb 10, 2025

Study contacts

Ingrid Murillo Jelsbak
Contact
ingrid.murillo@biofabri.es
+34 986 33 04 00 ext. 307
Andrea García Silva
Contact
a.garciasilva@biofabri.es
+34 986 33 04 00 ext. 309
Mark Hatherill
principal investigator · University of Cape Town, Faculty of Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mtbvac

Start the discussion